• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    4/29/24 8:06:58 AM ET
    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Deciphera Pharmaceuticals (NASDAQ:DCPH) stock rose 71.0% to $25.05 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
    • Koninklijke Philips (NYSE:PHG) shares moved upwards by 40.91% to $29.69. The company's market cap stands at $26.9 billion. The company's, Q1 earnings came out today.
    • Akanda (NASDAQ:AKAN) shares moved upwards by 25.63% to $0.13. The company's market cap stands at $1.5 million.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 22.62% to $2.97. The market value of their outstanding shares is at $16.1 million.
    • Scorpius Holdings (AMEX:SCPX) shares increased by 22.6% to $0.21. The company's market cap stands at $7.4 million.
    • NKGen Biotech (NASDAQ:NKGN) shares rose 11.8% to $1.8. The company's market cap stands at $41.0 million.

    Losers

    • Addex Therapeutics (NASDAQ:ADXN) shares declined by 53.9% to $7.43 during Monday's pre-market session. The market value of their outstanding shares is at $7.9 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock declined by 20.53% to $1.2. The company's market cap stands at $1.5 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock declined by 11.19% to $14.16. The company's market cap stands at $14.6 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) stock declined by 10.44% to $0.61. The market value of their outstanding shares is at $15.2 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock decreased by 10.01% to $1.17. The company's market cap stands at $5.1 million.
    • Mereo BioPharma Group (NASDAQ:MREO) shares decreased by 8.03% to $2.52. The market value of their outstanding shares is at $353.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AKAN
    $AVTX
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    3/6/26 10:05:20 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/27/26 4:34:26 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philips Sonicare unveils two new electric toothbrush ranges alongside refreshed brand direction

    Sonicare "Feel the Care" invites people to experience the 'Sonicare Feeling' that transforms your daily routine into a ritual of self-care.CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in oral healthcare, today unveiled two new Philips Sonicare electric toothbrush ranges, the integration of Next-Generation Sonicare technology, along with branding, packaging and sustainability updates that all reflect the brand's bold new platform, "Feel the Care." The refreshed brand and product lineup is designed to inspire consumers to elevate their daily oral care routine with advanced brushing technology.

    3/5/26 9:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments

    March 4, 2026 CE Marked and 510(k) pending, Rembra's advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real timeWith the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging and trauma, helping to improve comfort for complex patients and may reduce the need for rescansNext-generation NanoPanel Precise XD detector with AI is built for dose-efficient, high-resolution imaging to support clear visualization and delineation of anatomical structures Amsterdam,

    3/4/26 4:35:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments

    March 3, 2026 With a total budget of EUR 21.5 million, the four-year SHERPA research project is coordinated by Philips and co-funded by the EU Innovative Health Initiative (IHI) and industry partnersThe project focuses on developing automated workflows for minimally invasive neurovascular and tumor treatments – clinical procedures where staffing levels and specialized expertise are in short supplyThe clinical studies are being conducted at University Medical Center Utrecht, St Antonius Hospital, University Medical Center Hamburg-Eppendorf, Hôpital Bicêtre AP-HP, and Hospital de la Santa Creu i Sant PauOn March 4 (16:30 - 17:30 CET), SHERPA will be featured at the European Congress of Radiol

    3/3/26 4:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:32 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:06 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma downgraded by Jefferies with a new price target

    Jefferies downgraded Mereo BioPharma from Buy to Hold and set a new price target of $0.50

    12/30/25 7:20:11 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    6/2/25 12:11:05 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    5/7/25 4:05:15 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Philips proposes to re-appoint CEO Roy Jakobs

    February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. The proposal will be submitted for approval at the upcoming Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. "Roy Jakobs has demonstrated clear leadership, strong execution

    2/10/26 12:55:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AKAN
    $AVTX
    $BDRX
    Financials

    Live finance-specific insights

    View All

    Emergency Care Holdings Acquires Philips Emergency Care Business, Launching Global Emergency Care Platform

    Transaction establishes a scalable platform positioned for consolidation and growth in a $26B global emergency medical products market Emergency Care Holdings (ECH), a platform backed by Bridgefield Capital, today announced the completion of its acquisition of the Philips Emergency Care business from Koninklijke Philips N.V. (NYSE:PHG). The business will operate as Heartstream and continue to market select products under a Philips brand license. The acquisition represents the launch of ECH's global platform strategy focused on building a leading portfolio of emergency medical technology companies serving the pre-hospital care market. The emergency medical products sector exceeds $26 bil

    1/14/26 10:31:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro

    12/4/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

    Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025 Title:  Addex Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Upd

    12/1/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care